Literature DB >> 9223268

Immunity to retroviral infection: the Friend virus model.

K J Hasenkrug1, B Chesebro.   

Abstract

Friend virus infection of adult immunocompetent mice is a well established model for studying genetic resistance to infection by an immunosuppressive retrovirus. This paper reviews both the genetics of immune resistance and the types of immune responses required for recovery from infection. Specific major histocompatibility complex (MHC) class I and II alleles are necessary for recovery, as is a non-MHC gene, Rfv-3, which controls virus-specific antibody responses. In concordance with these genetic requirements are immunological requirements for cytotoxic T lymphocyte, T helper, and antibody responses, each of which provides essential nonoverlapping functions. The complexity of responses necessary for recovery from Friend virus infection has implications for both immunotherapies and vaccines. For example, it is shown that successful passive antibody therapy is dependent on MHC type because of the requirement for T cell responses. For vaccines, successful immunization requires priming of both T cell and B cell responses. In vivo depletion experiments demonstrate different requirements for CD8(+) T cells depending on the vaccine used. The implications of these studies for human retroviral diseases are discussed.

Entities:  

Mesh:

Year:  1997        PMID: 9223268      PMCID: PMC33712          DOI: 10.1073/pnas.94.15.7811

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  93 in total

1.  Immunosuppression by leukemia viruses. I. Effect of Friend disease virus on cellular and humoral hemolysin responses of mice to a primary immunization with sheep erythrocytes.

Authors:  W S Ceglowski; H Friedman
Journal:  J Immunol       Date:  1968-09       Impact factor: 5.422

2.  Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex.

Authors:  B Chesebro; K Wehrly
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

3.  Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum.

Authors:  M Bahmanyar; A Fayaz; S Nour-Salehi; M Mohammadi; H Koprowski
Journal:  JAMA       Date:  1976-12-13       Impact factor: 56.272

4.  Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens.

Authors:  B Chesebro; K Wehrly; M Cloyd; W Britt; J Portis; J Collins; J Nishio
Journal:  Virology       Date:  1981-07-15       Impact factor: 3.616

5.  Variable synthesis and expression of E alpha and Ae (E beta) Ia polypeptide chains in mice of different H-2 haplotypes.

Authors:  P P Jones; D B Murphy; H O McDevitt
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

6.  Leukemia virus-induced immunosuppression. IX. Depression of delayed hypersensitivity and MIF production after infection of mice with Friend leukemia virus.

Authors:  R F Mortensen; W S Ceglowski; H Friedman
Journal:  J Immunol       Date:  1973-12       Impact factor: 5.422

7.  Persistence of infectious Friend virus in spleens of mice after spontaneous recovery from virus-induced erythroleukemia.

Authors:  B Chesebro; M Bloom; K Wehrly; J Nishio
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

8.  Rfv-1 and Rfv-2, two H-2-associated genes that influence recovery from Friend leukemia virus-induced splenomegaly.

Authors:  B Chesebro; K Wehrly
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

9.  Leukemia virus-induced immunosuppression. X. Depression of T cell-mediated cytotoxicity after infection of mice with Friend leukemia virus.

Authors:  R F Mortensen; W S Ceglowski; H Friedman
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

10.  The effect of histocompatibility-2 type on response to friend leukemia virus in mice.

Authors:  F Lilly
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

View more
  70 in total

1.  Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus.

Authors:  U Dittmer; B Race; K J Hasenkrug
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Use of a transient assay for studying the genetic determinants of Fv1 restriction.

Authors:  M Bock; K N Bishop; G Towers; J P Stoye
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  A conserved mechanism of retrovirus restriction in mammals.

Authors:  G Towers; M Bock; S Martin; Y Takeuchi; J P Stoye; O Danos
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

4.  Serial infection of diverse host (Mus) genotypes rapidly impedes pathogen fitness and virulence.

Authors:  Jason L Kubinak; Douglas H Cornwall; Kim J Hasenkrug; Frederick R Adler; Wayne K Potts
Journal:  Proc Biol Sci       Date:  2015-01-07       Impact factor: 5.349

5.  Reduction of retrovirus-induced immunosuppression by in vivo modulation of T cells during acute infection.

Authors:  Hong He; Ronald J Messer; Shimon Sakaguchi; Guojun Yang; Shelly J Robertson; Kim J Hasenkrug
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  In vitro and in vivo analyses of regulatory T cell suppression of CD8+ T cells.

Authors:  Kim J Hasenkrug; Lara M Myers
Journal:  Methods Mol Biol       Date:  2011

7.  Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.

Authors:  Camilla Patrizia Hrycak; Sonja Windmann; Wibke Bayer
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

8.  Trim5alpha protein restricts both HIV-1 and murine leukemia virus.

Authors:  Melvyn W Yap; Sébastien Nisole; Clare Lynch; Jonathan P Stoye
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

9.  Toll-like receptor 7 inhibits early acute retroviral infection through rapid lymphocyte responses.

Authors:  Edward P Browne
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

10.  Dissecting the immune response to moloney murine sarcoma/leukemia virus-induced tumors by means of a DNA vaccination approach.

Authors:  G Milan; A Zambon; M Cavinato; P Zanovello; A Rosato; D Collavo
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.